NanoViricides to Present Broad-Spectrum Antiviral Platform at LSX World Congress 2025
TL;DR
NanoViricides presents at LSX World Congress 2025, offering investors early access to its broad-spectrum antiviral platform targeting multiple high-value viral markets.
NanoViricides uses nanoviricide technology licensed from TheraCour to develop polymeric micelle drugs that encapsulate antivirals like remdesivir for enhanced efficacy against viral escape.
NanoViricides' broad-spectrum antiviral platform could revolutionize treatment for diseases like COVID, RSV, and influenza, potentially saving millions of lives worldwide.
NanoViricides develops nanoviricides that act like decoy viruses, trapping and neutralizing actual viruses through innovative polymeric micelle technology licensed from TheraCour.
Found this article helpful?
Share it with your network and spread the knowledge!
NanoViricides Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, announced its presentation scheduled for the Life Science Executive Partnering (LSX) World Congress 2025 in Boston on September 17 at 12:30 p.m. The company specializes in developing broad-spectrum antiviral drugs designed to resist viral escape using its proprietary nanoviricide technology platform licensed from TheraCour Pharma Inc.
The company's lead drug candidate, NV-387, represents a significant advancement in antiviral therapy as a broad-spectrum treatment targeting respiratory syncytial virus (RSV), COVID-19, long COVID, influenza, and other respiratory viral infections, along with MPOX/smallpox infections. Another advanced candidate, NV-HHV-1, focuses on shingles treatment. The company is currently prioritizing advancing NV-387 into Phase II human clinical trials, though specific timelines for investigational new drug (IND) filings remain dependent on external collaborators and consultants.
NanoViricides' platform includes two distinct COVID-19 candidates: NV-CoV-2, which does not encapsulate remdesivir, and NV-CoV-2-R, which incorporates remdesivir within its polymeric micelles. The company believes the remdesivir-encapsulated version may have smoother regulatory pathways given remdesivir's existing FDA approval, provided comparable safety profiles can be demonstrated. Both candidates were developed independently by NanoViricides without involvement from Gilead, remdesivir's original developer.
The company's technology licensing framework, established through a Memorandum of Understanding with TheraCour Pharma Inc., provides exclusive, sub-licensable rights for specific antiviral applications. This business model, in place since the company's 2005 foundation, covers numerous viral diseases including HIV/AIDS, hepatitis B and C, rabies, herpes simplex viruses, influenza strains, dengue viruses, Japanese encephalitis, West Nile virus, and Ebola/Marburg viruses. Additional licenses for RSV, poxviruses, and enteroviruses may be pursued pending successful initial research outcomes.
Investors can access the latest company updates through the corporate newsroom available at https://ibn.fm/NNVC. The full press release detailing the LSX World Congress presentation is accessible at https://ibn.fm/uoB3n. NanoViricides emphasizes the inherent risks of pharmaceutical development, noting the lengthy timelines, substantial capital requirements, and uncertainties regarding clinical trial success despite promising laboratory results against various viruses.
The presentation at this major industry gathering highlights the growing importance of broad-spectrum antiviral platforms capable of addressing multiple viral threats simultaneously, particularly those designed to overcome viral escape mechanisms that often limit traditional antiviral therapies.
Curated from InvestorBrandNetwork (IBN)
